Catalog No.
KVV13101
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for Monkeypox Virus A35R Antigen has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Monkeypox Virus A35R Antigen present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-labeled Monkeypox Virus A35R antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Monkeypox Virus A35R Antigen bound in the initial step. The color development is stopped and the intensity of the color is measured.
Target
A35R
Applications
Used for the quantitative determination of Monkeypox Virus A35R Antigen concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
375 pg/mL - 24,000 pg/mL
Sensitivity
158.4 pg/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (pg/mL)
|
8186.41
|
2041.24
|
494.61
|
7801.74
|
1901.42
|
389.52
|
|
Standard deviation
|
242.33
|
82.65
|
52.65
|
317.20
|
100.94
|
39.19
|
|
CV (%)
|
2.96
|
4.05
|
10.64
|
4.07
|
5.31
|
10.06
|
Recovery
70-100%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃.
A Pathogen-Mimicking Monkeypox Virus Nanovaccine Inspired by Assembly of Viral Antigens with β-Glucan and Dendrimer., PMID:40366370
Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice., PMID:40105863
Immunogenicity of monkeypox virus surface proteins and cross-reactive antibody responses in vaccinated and infected individuals: implications for vaccine and therapeutic development., PMID:39994775
Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein., PMID:39861905
Chemical cross-linking facilitates antigen uptake and presentation and provides improved protection from Mpox with a dual-antigen subunit vaccine., PMID:39781294
Long-Lasting Protection and Dose Optimization of MPXV Polyvalent Mpox mRNA Vaccines Against Lethal Vaccinia Virus Challenge in Mice., PMID:39726255
A penta-component mpox mRNA vaccine induces protective immunity in nonhuman primates., PMID:39639037
Single-chain A35R-M1R-B6R trivalent mRNA vaccines protect mice against both mpox virus and vaccinia virus., PMID:39423738
Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines., PMID:39417768
Analysis of binding and authentic virus-neutralizing activities of immune sera induced by various monkeypox virus antigens., PMID:38829493
Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus., PMID:38787725
Levels of antibodies against the monkeypox virus compared by HIV status and historical smallpox vaccinations: a serological study., PMID:38767199
In silico development of a novel anti-mutation, multi-epitope mRNA vaccine against MPXV variants of emerging lineage and sub-lineages by using immunoinformatics approaches., PMID:38450722
Screening, Expression and Identification of Nanobody Against Monkeypox Virus A35R., PMID:38076734
Immunoinformatic Approach for Rational Identification of Immunogenic Peptides Against Host Entry and/or Exit Mpox Proteins and Potential Multiepitope Vaccine Construction., PMID:37804521
Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice., PMID:37800627
mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge., PMID:37739969
Duration of humoral immunity from smallpox vaccination and its cross-reaction with Mpox virus., PMID:37709783
Multi-Body Biomarker Entrapment System: An All-Encompassing Tool for Ultrasensitive Disease Diagnosis and Epidemic Screening., PMID:37486783
Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice., PMID:37429529
Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity., PMID:37300753
Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus., PMID:37288876
Design peptide and multi-epitope protein vaccine candidates against monkeypox virus using reverse vaccinology approach: an in-silico study., PMID:37154825
Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches., PMID:36993967
Rational development of multicomponent mRNA vaccine candidates against mpox., PMID:36947428
Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens., PMID:36687315
Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine., PMID:18482742
For research use only. Not for human or drug use.
